Authority Without Infrastructure: A Researcher's Experience With Specimen Access Barriers in Sudden Unexpected Infant Death Research.

An infant death that remains unexplained after a comprehensive medicolegal investigation does not establish the absence of an underlying biological mechanism. Investigation of a specific research hypothesis may nevertheless be limited when suitable specimens or preservation records are unavailable. This editorial describes non-systematic exploratory outreach undertaken during development of a proposed National Institutes of Health (NIH) R21 study and considers relevant legal provisions in Florida and California. The outreach identified concerns involving staffing, workflow, authorization, liability, laboratory access, and specimen storage but secured no conditional collection-site commitment. These project-specific observations are hypothesis-generating; they do not establish the frequency of specimen unavailability or a national infrastructure deficiency. A limited, voluntary pilot, potentially using existing research networks, repositories, or academic partnerships, could evaluate prospective specimen collection during routine sudden unexpected infant death (SUID) investigations. It would assess specimen adequacy, workload, cost, and authorization procedures while preserving medicolegal authority and avoiding delays to examinations or body release. Transfer, testing, and secondary use would require appropriate governance. Projects would undergo independent scientific and feasibility review, without priority for the author's Metabolic Vulnerability Index (MVI) framework. Successful collection would support operational feasibility under the tested conditions, not establish the clinical validity or causal relevance of MVI or other proposed biological mechanisms.